Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q7325035> ?p ?o }
Showing triples 1 to 40 of
40
with 100 triples per page.
- Q7325035 description "American biochemist".
- Q7325035 description "American biochemist".
- Q7325035 subject Q3919876.
- Q7325035 subject Q5312304.
- Q7325035 subject Q6351751.
- Q7325035 subject Q6967136.
- Q7325035 subject Q7200943.
- Q7325035 subject Q8412806.
- Q7325035 subject Q8567705.
- Q7325035 subject Q8763960.
- Q7325035 abstract "<https://www.bidmc.org/Centers-and-Departments/Departments/Surgery/Surgery-News/2015/September/New-News-Article-Page.aspx> Richard D. Cummings, Ph.D. is Visiting Professor of Surgery at Beth Israel Deaconess Medical Center and Harvard Medical School in Boston, MA, a position he assumed in September 1, 2015. Before moving to BIDMC/HMS, Cummings was the William Patterson Timmie Professor and Chair of the Department of Biochemistry at Emory University School of Medicine in Atlanta, Georgia. At Emory, Cummings was a founder in 2007 of the Emory Glycomics Center. Prior to moving to Emory, Cummings was the Ed Miller Endowed Chair in Molecular Biology, the George Lynn Cross Professor in Biochemistry, and Professor of Biochemistry and Molecular Biology at the University of Oklahoma Health Sciences Center, College of Medicine, in Oklahoma City, Oklahoma. He was the founder in 1999 of the Oklahoma Center for Medical Glycobiology. Prior to his position in Oklahoma, Cummings was Professor of Biochemistry and Molecular Biology at the University of Georgia and Associate Director of the Complex Carbohydrate Research Center there. He is a co-founder, among many other well-known scientists, of the fields of glycomics and glycobiology. His research, which has been funded by the National Institutes of Health since 1984, has focused on the biochemical and molecular regulation of cellular metabolism and function. His work emphasizes the roles of glycoconjugates in cell adhesion and cell signaling. In his biochemical studies he is exploring the fundamental pathways of glycoconjugate biosynthesis and alterations in biosynthesis in human and animal diseases. He is also exploring in the roles of proteins and lectins that recognize glycans, as well as anti-glycan antibodies, in biological pathways and disease, including inflammation, autoimmunity, infectious diseases, and cancer. Cummings has over 250 peer-reviewed publications in the field, along with over 60 review articles, and dozens of book chapters. Cummings is an elected Fellow of the American Association for the Advancement of Science (2014), and a past President of the Society for Glycobiology (2001). In 2008 he received the Karl Meyer from the Society for Glycobiology in recognition of his many contributions to the field. He has held numerous leadership positions in academia and has been a leader in industry and government involvement in scientific reviews and decision making. Cummings is a co-Editor of the 1st (1999) and 2nd Editions (2009) of Essentials of Glycobiology, the first textbook in the field of glycobiology, and is a co-Editor of the upcoming 3rd Edition of that textbook. He is also a co-Editor of Handbook of Glycomics, which provides a comprehensive overview of the emerging field of glycomics, and a co-Editor of Galectins: Methods and Protocols. In addition, Cummings currently has 29 US Patents in the field of biotechnology and glycobiology. Cummings is the Chair of the Consortium of Functional Glycomics, a world-wide organization that is a comprehensive resource for functional glycomics. Cummings is also the Director of the National Center for Functional Glycomics, which relocated in 2015 from Emory to BIDMC/HMS, and develops and offers a variety of glycan microarray technologies for researchers in the field. Cummings graduated from Isabella High School in Chilton County, AL and received his B.S. in Biology from the University of Montevallo. He received his Ph.D. in Biology (biochemistry) from The Johns Hopkins University, where he trained with Dr. Stephen A. Roth, and was a Postdoctoral Fellow in the Division of Hematology/Oncology at Washington University in St. Louis, where he trained with Dr. Stuart A. Kornfeld.Cummings is a co-founder, along with Rodger P. McEver, MD, and Richard Alvarez, MBA, of Selexys Pharmaceuticals Corporation, where he initially served as President and Chief Scientific Officer. Selexys is based in Oklahoma City, Oklahoma. The emphasis of the company is developing treatments for inflammatory disorders.".
- Q7325035 wikiPageExternalLink www.functionalglycomics.org.
- Q7325035 wikiPageExternalLink ?term=glycobiology.
- Q7325035 wikiPageExternalLink 9780123736000.
- Q7325035 wikiPageExternalLink www.selexys.com.
- Q7325035 wikiPageWikiLink Q3919876.
- Q7325035 wikiPageWikiLink Q5312304.
- Q7325035 wikiPageWikiLink Q6351751.
- Q7325035 wikiPageWikiLink Q6967136.
- Q7325035 wikiPageWikiLink Q7200943.
- Q7325035 wikiPageWikiLink Q8412806.
- Q7325035 wikiPageWikiLink Q8567705.
- Q7325035 wikiPageWikiLink Q8763960.
- Q7325035 name "Cummings, Richard D.".
- Q7325035 shortDescription "American biochemist".
- Q7325035 type Person.
- Q7325035 type Agent.
- Q7325035 type Person.
- Q7325035 type Agent.
- Q7325035 type NaturalPerson.
- Q7325035 type Thing.
- Q7325035 type Q215627.
- Q7325035 type Q5.
- Q7325035 type Person.
- Q7325035 comment "<https://www.bidmc.org/Centers-and-Departments/Departments/Surgery/Surgery-News/2015/September/New-News-Article-Page.aspx> Richard D. Cummings, Ph.D. is Visiting Professor of Surgery at Beth Israel Deaconess Medical Center and Harvard Medical School in Boston, MA, a position he assumed in September 1, 2015. Before moving to BIDMC/HMS, Cummings was the William Patterson Timmie Professor and Chair of the Department of Biochemistry at Emory University School of Medicine in Atlanta, Georgia.".
- Q7325035 label "Richard D. Cummings".
- Q7325035 givenName "Richard D.".
- Q7325035 name "Cummings, Richard D.".
- Q7325035 name "Richard D. Cummings".
- Q7325035 surname "Cummings".